Hassan Fatma E, Sakr Hader I, Mohie Passant M, Suliman Howayda Saeed, Mohamed Ayman Saber, Attia Mohamed H, Eid Dalia M
Department of Medical Physiology, Faculty of Medicine, Cairo University, Egypt.
Department of Medical Physiology, Batterjee Medical College, Jeddah, Saudi Arabia.
Ann Med. 2021 Dec;53(1):1032-1040. doi: 10.1080/07853890.2021.1916069.
Fibromyalgia (FM) is characterized by musculoskeletal pain, fatigue, sleep and memory disturbance. There is no definitive cure yet for FM-related health problems. Peroxisome proliferator-activated receptor's (PPAR's) activation is associated with insulin sensitisation and improved glucose metabolism. PPAR-γ was reported to alleviate FM allodynia. Limited data are discussing its effect on motor disorders.
To investigate the potential effect of PPAR-γ agonists (pioglitazone, as one member of thiazolidinediones (TZD)) on motor dysfunction in reserpine-induced FM in a rat model.
Thirty-six male Wistar rats were divided into negative control ( = 9) and reserpine-induced FM ( = 27) groups. The latter was subdivided into three equal subgroups ( = 9), positive control (untreated FM model), pioglitazone-treated and GW9662-treated. We evaluated muscle functions and activity of chloramphenicol acetyltransferase, superoxide dismutase, malondialdehyde, and serum levels of interleukin-8 and monocyte chemoattractant protein-1.
Pioglitazone significantly relieved fatigue, improved muscle performance, reduced inflammatory cytokines and enhanced antioxidant's activity, while GW9662, a known PPAR-γ antagonist, aggravated the FM manifestations in the rat model.
PPAR-γ agonists show a promising role against FM-associated motor dysfunctions.
纤维肌痛（FM）的特征为肌肉骨骼疼痛、疲劳、睡眠和记忆障碍。目前尚无针对FM相关健康问题的确切治愈方法。过氧化物酶体增殖物激活受体（PPAR）的激活与胰岛素敏感性增加和葡萄糖代谢改善有关。据报道，PPAR-γ可减轻FM的痛觉过敏。关于其对运动障碍影响的数据有限。
在大鼠模型中研究PPAR-γ激动剂（吡格列酮，作为噻唑烷二酮类（TZD）的一员）对利血平诱导的FM运动功能障碍的潜在影响。
将36只雄性Wistar大鼠分为阴性对照组（n = 9）和利血平诱导的FM组（n = 27）。后者再分为三个相等的亚组（n = 9），即阳性对照组（未治疗的FM模型）、吡格列酮治疗组和GW9662治疗组。我们评估了肌肉功能以及氯霉素乙酰转移酶、超氧化物歧化酶、丙二醛的活性，以及白细胞介素-8和单核细胞趋化蛋白-1的血清水平。
吡格列酮显著缓解疲劳，改善肌肉性能，降低炎性细胞因子水平并增强抗氧化剂活性，而已知的PPAR-γ拮抗剂GW9662则加重了大鼠模型中的FM表现。
PPAR-γ激动剂在对抗FM相关运动功能障碍方面显示出有前景的作用。
